Optovue (Visionix)

U.S. ophthalmic-OCT specialist — pioneered commercial OCT angiography (OCT-A) with the Avanti / AngioVue platform. Acquired by Israeli ophthalmic-equipment group Visionix in 2021 and now operates as part of the Visionix portfolio. Niche but durable presence in retinal practices that adopted OCT-A early and built clinical workflows around it.

Company history

2003 — founded.
2009 — RTVue Fourier-domain OCT enters clinical use.
2014–2015 — AngioVue OCT-Angiography module launches commercially — among the earliest OCT-A platforms at clinical scale.
2021 — acquired by Visionix Group; product line continues under Optovue / Visionix branding.
2020s — Solix multi-modal platform extends the line.

Product line

Avanti / Avanti Widefield — spectral-domain OCT with AngioVue OCT-A module.
AngioVue — OCT-A module on Avanti / Solix platforms.
Solix — current-generation multi-modal retinal imaging platform (OCT + OCT-A + fundus).
iVue — entry / general-ophthalmology SD-OCT.
iScan — telemedicine / screening configuration.

Distinctive technology

Early OCT-A clinical adoption — Optovue was an early commercial OCT-A vendor; clinical-evidence base for OCT-A retinal disease assessment is heavily weighted toward Optovue / AngioVue acquisitions.
Split-spectrum amplitude-decorrelation angiography (SSADA) — Optovue's OCT-A reconstruction technique.
Widefield retinal imaging — extended-FOV scans on Avanti Widefield / Solix.

Market position

Niche but durable in retinal practices that committed to OCT-A early — particularly diabetic-retinopathy programs and academic retina centers. Smaller installed base than Zeiss Cirrus, Heidelberg Spectralis, or Topcon Triton, but loyal user base.

Refurb posture

Modest refurb supply — Avanti / AngioVue units appear in retinal-clinic upgrades.
Software / OCT-A license version drives clinical capability.
Vendor lock-in on serial patient comparison applies as with all OCT vendors.